Background

The IDEA collaboration showed that the type and duration of adjuvant chemotherapy in stage III colon cancer (CC) could be adjusted according to the schedule of chemotherapy and the level of risk. We aimed at evaluating the implementation of IDEA’s results in real-life practice for stage III CC.

Material and Methods

All clinicians registered in the French oncology cooperative groups GERCOR, FFCD, and UNICANCER GI mailing lists were invited to participate to an online anonymized nationwide survey from January 30, 2019 to March 31, 2019. Proportions were compared using the χ² test.

Results

A total of 213 physicians answered the survey. Of these, 173 (81%) considered that 3 months of adjuvant chemotherapy was the new standard of care for low-risk (pT1-3/N1) stage III CC, and 99% considered that 6 months remained the standard of care for high-risk (pT4 and/or pN2) stage III CC. In patients under 70 years, capecitabine and oxaliplatin (CAPOX) for 3 months was prescribed by 74% of the participants in low-risk CC, whereas 6 months of 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) was preferred for high-risk CC in 94% of cases. For patients over 70 years with good performance status and no comorbidities, 172 (81%) physicians prescribed oxaliplatin-based chemotherapy for low-risk CC (3 months, 144 of 172%; 88%), and 200 (94%) physicians prescribed oxaliplatin-based adjuvant chemotherapy for high-risk CC (6 months, 199 of 200%; 99.5%).

Conclusions

The IDEA results have been practice-changing as French physicians have implemented 3 months of CAPOX for patients with low-risk stage III CC, substituting from 6 months of FOLFOX, which remains the preferred regimen for high-risk patients.

中文翻译：

---

IDEA 合作研究结果对法国 III 期结肠癌患者临床实践的影响：全国 GERCOR - PRODIGE 调查

背景

IDEA合作表明，III期结肠癌（CC）辅助化疗的类型和持续时间可以根据化疗的时间表和风险水平进行调整。我们旨在评估 IDEA 结果在 III 期 CC 的现实生活实践中的实施情况。

材料与方法

在法国注册的肿瘤协作组GERCOR，全面申报，并UNICANCER GI邮件列表的所有临床医生应邀从2019年1月30，参与到网上匿名全国范围内的调查，以3月31日，2019年比重分别使用比较χ ²测试。

结果

共有 213 名医生回答了调查。其中，173 人 (81%) 认为 3 个月的辅助化疗是低危 (pT1-3/N1) III 期 CC 的新护理标准，99% 的人认为 6 个月仍然是高危 (pT1-3/N1) 期的护理标准。 - 风险（pT4 和/或 pN2）III 期 CC。在 70 岁以下的患者中，74% 的低危 CC 参与者处方卡培他滨和奥沙利铂 (CAPOX) 3 个月，而高危 CC 患者首选 6 个月的 5-氟尿嘧啶、亚叶酸和奥沙利铂 (FOLFOX) CC 在 94% 的情况下。对于体力状态良好且无合并症的 70 岁以上患者，172 名 (81%) 医生为低危 CC 开出以奥沙利铂为基础的化疗（3 个月，172% 中的 144 名；88%），200 名 (94%) 医生开出高危 CC 的基于奥沙利铂的辅助化疗（6 个月，200% 中的 199；99.5%）。

结论

IDEA 结果已经改变了实践，因为法国医生对低危 III 期 CC 患者实施了 3 个月的 CAPOX，取代了 6 个月的 FOLFOX，后者仍然是高危患者的首选方案。